[Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines]

A Z Vinarov; L G Spivak; A V Mironov

[Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines]

Urologiia. 2017 Sep:(4):120-128.

[Article in Russian]

Authors

A Z Vinarov^{1

2}, L G Spivak^{1

2}, A V Mironov^{1

2}

Affiliations

¹ I.M. Sechenov First MSMU of Minzdrav of Russia, Moscow, Russia.
² Medical Department at GlaxoSmithKline, Moscow, Russia.

PMID: 28952704

Abstract

The article reviews clinical trials on the effectiveness of combination therapy with 5-reductase inhibitors and -blockers in men with benign prostatic hyperplasia (BPH). These trials have demonstrated a significant improvement in the symptoms and quality of life in this group of patients. The authors outline main strategies offered by the Russian clinical guidelines for BPH patients.

Keywords: 5-reductase inhibitors; Avodart; Duodart; benign prostatic hyperplasia; clinical trials; combination therapy; disease progression; dutasteride; lower urinary tract symptoms.

Publication types

Randomized Controlled Trial

MeSH terms

5-alpha Reductase Inhibitors / therapeutic use*
Adrenergic alpha-Antagonists / therapeutic use*
Drug Combinations
Dutasteride / therapeutic use*
Humans
Male
Middle Aged
Practice Guidelines as Topic
Prostatic Hyperplasia / drug therapy*
Prostatic Hyperplasia / physiopathology
Prostatic Hyperplasia / psychology
Quality of Life
Sulfonamides / therapeutic use*
Tamsulosin

Substances

5-alpha Reductase Inhibitors
Adrenergic alpha-Antagonists
Drug Combinations
Sulfonamides
Tamsulosin
Dutasteride